[ * ] = Certain confidential information  {E1 contained}  in this document,  {E2 marked}  by brackets, has been  {E3 omitted}  and  {E4 filed}  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  {E111 amended}  . CONFIDENTIAL

EXECUTION VERSION

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this "Agreement")  {E5 dated}  as of  May 31, 2017  (the "Effective  Date  "), is  {E6 made}  and  {E7 entered}  into by and between Array BioPharma Inc., a company  {E8 organized}  under the laws of Delaware and  {E9 having}  its principal place of business at 3200 Walnut Street, Boulder, CO 80301 USA, ("Array") and Ono Pharmaceutical Co., Ltd., a company duly  {E10 organized}  and  {E11 existing}  under the laws of Japan,  {E12 having}  offices and principal place of business at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan ("Ono"). BACKGROUND

A. Array  now   {E13 owns}  or  {E14 controls}  certain patents,  know  -how and other intellectual property  {E15 relating}  to the Products (as  {E16 defined}  below);

B. Ono has {E113 experience} in developing, marketing and  {E17 distributing}  pharmaceutical products;

C. Array and Ono  {E18 wish}  to  {E19 collaborate}  on the further {E114 development}, {E115 manufacture} and {E116 commercialization} of the Products, with Ono  {E20 taking}  the lead role in such {E117 efforts} in the Ono Territory (as  {E21 defined}  below); and

D. Array is willing to  {E22 grant}  to Ono, and Ono desires to  {E23 obtain}  , certain exclusive rights and licenses with respect to the {E115 manufacture}, {E119 registration} and {E116 commercialization} of the Products in the Ono Territory. Array will  {E24 retain}  the right to  {E25 develop}  and  {E26 commercialize}  the Products for the Array Territory, all on the terms and conditions set forth herein. NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein  {E27 contained}  , and for other good and valuable consideration, the {E121 receipt} and sufficiency of which are hereby  {E28 acknowledged}  , the Parties hereby  {E29 agree}  as  follows  :

ARTICLE I   DEFINITIONS

1.1 "Affiliate" of a Party means any person, corporation or other entity that, directly or indirectly, controls, is controlled by, or is under common control with such Party, as the case may be. As  {E30 used}  in this Section 1.1, the word "control" ( {E31 including}  , with correlative meaning, the terms "controlled by" or "under the common control with") shall mean the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of more than fifty percent (50%) of the voting share capital in such person, corporation, or other entity, or by contract or otherwise. 1.2 "Annual Net Sales" means the Net Sales generated over any given Fiscal Year, or in the case of the Fiscal Year in which the First Commercial {E123 Sale} of the first Product occurs, the Net Sales generated during the period commencing on the date of such First Commercial {E123 Sale} and continuing until the end of such Fiscal Year. [ * ] = Certain confidential information  {E32 contained}  in this document,  {E33 marked}  by brackets, has been  {E34 omitted}  and  {E35 filed}  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  {E36 amended}  . 1.3 "Applicable Regulatory Exclusivity Period" means with respect to a particular Product and particular country in the Ono Territory, the period commencing upon the {E124 receipt} of the first grant of Regulatory Exclusivity in such country for such Product ("Initial Regulatory Exclusivity"), and continuing until the later of (i) the {E125 expiration} of such Initial Regulatory Exclusivity, or (ii) if any subsequent grant of Regulatory Exclusivity is received prior the {E129 expiration} of the Initial Regulatory Exclusivity, then until the {E128 expiration} of such additional Regulatory Exclusivity if such {E128 expiration} would occur after the {E129 expiration} of the Initial Regulatory Exclusivity. 1.4 "Array Know-How" means, subject to Section 4.4(c)(ii), all scientific, medical, technical, manufacturing, marketing, regulatory, market access and other information (including clinical data and other related information generated in compliance with CDISC standards) relating to Binimetinib, Encorafinib, a Product and/or any Companion Diagnostic useful with respect to the {E130 Development}, {E131 Manufacturing}, {E132 registration} (including {E133 registration} for MAA) or {E134 Commercialization} of a Product (including the Data), to the extent Controlled by Array or its Controlled Affiliates as of the Effective  Date  or during the  term  of this Agreement, and needed by or reasonably useful to Ono in order for Ono to exercise its rights or perform its obligations under this Agreement. Notwithstanding the foregoing or Section 1.18 (Data) below, but subject to Section 2.4 (Future Third Party Partners), Array Know-How shall in any case  {E37 include}  all such items that are  {E38 generated}  by or under authority of Array, or any of its Affiliates, in connection with {E130 Development} {E131 Manufacturing}, and/or {E134 Commercialization} of the Product during the  term  of this Agreement. 1.5 "Array Patents" means the Patents Controlled by Array or its Controlled Affiliates as of the Effective  Date  or during the  term  of this Agreement that:

(a)  are  {E39 listed}  on Exhibit 1.5; or

(b) but for the license  {E40 granted}  under this Agreement, would be  {E41 infringed}  by the {E130 Development}, {E131 Manufacturing}, {E140 registration}, {E141 packaging}, or {E134 Commercialization} of a Product in the Ono Territory ( {E42 including}  the {E143 identification} of patients who would  {E43 benefit}  from the Product  {E44 based}  on the presence or absence of  {E45 selected}  biomarkers); and

(c)  all {E144 additions}, {E145 divisions}, {E146 continuations}, {E147 substitutions}, {E148 re-issues}, {E149 re-examinations}, {E150 registrations}, patent  term  {E151 extensions}, supplemental protection certificates, and {E152 renewals} of any the Patents  {E46 listed}  on Exhibit 1.5 or to the extent the same would  {E47 satisfy}  the requirements of subsection (b) above. 1.1 "Array Territory" means all countries worldwide, excluding the Ono Territory. 2

[ * ] = Certain confidential information  {E48 contained}  in this document,  {E49 marked}  by brackets, has been  {E50 omitted}  and  {E51 filed}  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  {E52 amended}  . 1.2 "Binimetinib" means the compound known as MEK162, the chemical structure of which is depicted in Exhibit 1.7 as well as all salts, non-covalent complexes, hydrates, solvates, chelates, crystal polymorph or radiolabeled equivalent thereof. 1.3 "Business Days" means any  day  other than  Saturday ,  Sunday ,  a day  within Array's company-wide corporate holidays (for Array's obligations) or Ono's company-wide corporate holidays (for Ono's obligations) or any other  day  on which commercial banks in USA or Japan are authorized or required by law to remain closed. 1.4 "Calendar Year" means any period of time commencing on  January 1  and {E112 ending} on  the next December 31  unless otherwise noted. 1.5 "CDISC" means Clinical Data Interchange Standards Consortium which is an interdisciplinary nonprofit organization that establishes international standards for data {E154 collection}, {E155 interchange}, {E156 application}, and {E157 storage} for the purpose of promoting {E153 interoperation} of clinical research data. 1.6 "Change in Control" means, with respect to a Party, that any of the following occurs with respect to such Party after the Effective  Date  :

(a)  any "person" or "group" (as such terms are  {E53 defined}  below) (i) is or  {E54 becomes}  the "beneficial owner" (as  {E55 defined}  below, except that a "person" or "group" shall be  {E56 deemed}  to have "beneficial ownership" of all shares of capital stock or other equity interests if such person or group has the right to  {E57 acquire}  , whether such right is exercisable immediately or only after the passage of time), directly or indirectly, of shares of capital stock or other interests ( {E58 including}  partnership interests) of such Party then outstanding and normally  {E59 entitled}  (without regard to the {E158 occurrence} of any contingency) to  {E60 vote}  in the {E159 election} of the directors, managers or similar supervisory positions ("Voting Stock") of such Party  {E61 representing}  more than fifty percent (50%) of the total  {E62 voting}  power of all outstanding classes of Voting Stock of such Party or (ii) has the power, directly or indirectly, to  {E63 elect}  a majority of the members of such Party's board of directors or similar governing body;

(b) such Party  {E64 enters}  into a {E163 merger}, {E164 consolidation} or similar {E165 transaction} with another Person (whether or not such Party is the  {E65 surviving}  entity) and as a result of such {E163 merger}, {E164 consolidation} or similar {E165 transaction} the Persons that beneficially  {E66 owned}  , directly or indirectly, the shares of Voting Stock of such Party immediately prior to such {E167 transaction} cease to beneficially own, directly or indirectly, shares of Voting Stock of such Party  {E67 representing}  at least a majority of the total  {E68 voting}  power of all outstanding classes of Voting Stock of the  {E69 surviving}  Person in substantially the same proportions as their ownership of Voting Stock of such Party immediately prior to such {E167 transaction}; or

3

[ * ] = Certain confidential information  {E70 contained}  in this document,  {E71 marked}  by brackets, has been  {E72 omitted}  and  {E73 filed}  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  {E74 amended}  . (c)  such Party  {E75 sells}  or transfers to any Third Party, in one or more related {E168 transactions}, properties or assets  {E76 representing}  all or substantially all of such Party's assets to which this Agreement  {E77 relates}  . For the purpose of this definition of Change in Control: (i) "person" and "group" have the meanings  {E78 given}  such terms under Section 13(d) and 14(d) of the United States Securities Exchange Act of  1934  and the  term  "group"  {E79 includes}  any group  {E80 acting}  for the purpose of  {E81 acquiring}  ,  {E82 holding}  or disposing of securities within the meaning of Rule 13d-5(b)(1) under the aforesaid Act; (ii) a "beneficial owner" shall be determined in accordance with Rule 13d-3 under the aforesaid Act; (iii) the terms "beneficially owned" and "beneficially own" shall have meanings correlative to that of "beneficial owner"; and (iv)"Person" means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity or any government, any agency or political subdivisions thereof. Such "person" or "group" in Section 1.11(a), such  {E83 surviving}  Person in Section 1.11(b) or such Third Party in Section 1.11(c) shall be  {E84 referred}  to herein as "Acquirer". 1.7 "Clinical {E218 Studies}" means any human clinical {E218 study} of a Product, including without limitation Post-Approval Marketing Clinical {E171 Studies}. 1.8 "Combination Product" means any pharmaceutical {E173 preparations}, in any dosage strengths, formulations and methods of {E172 administration}, that combine Binimetinib or Encorafenib and one or more other active ingredients (other than Binimetinib or Encorafenib) in fixed dose combination, whether co-formulated or co-packaged. 1.9 "{E174 Commercialization}" means all {E175 processes} and {E176 activities} conducted to establish and maintain {E177 sales} for the Products, including {E178 offering} for {E182 sale}, {E180 distribution}, {E181 detailing}, {E182 selling} (including {E183 launch}), {E184 promoting}, {E185 importing}, {E186 exporting}, market access {E187 activities}, all marketing {E188 activities} undertaken prior to and after the {E189 launch} of the Products (including education and advertising {E190 activities}), {E191 branding}, {E192 developing} promotional materials, {E193 advertising}, {E194 organizing} speakers {E195 programs} and post-marketing safety {E196 surveillance} and {E197 reporting}. "Commercialize" and "Commercializing" shall have the correlative meanings. 1.10 "Companion Diagnostic" means an in vitro diagnostic medical device as defined in the European directive 98/79/EC; for the avoidance of doubt the  term  Companion Diagnostic includes companion diagnostics for a pharmaceutical product as defined in FDA's "Draft Guidance for Industry and Food and Drug Administration Staff - In Vitro Companion Diagnostic Devices". 1.11 "Control" ( {E85 including}  any variations such as "Controlled" and " {E86 Controlling}  "), in the context of intellectual property rights, data and/or other information, means that such Party or its Affiliate owns, is licensed or otherwise possesses rights to such intellectual property, data and/or information,

4

[ * ] = Certain confidential information  {E87 contained}  in this document,  {E88 marked}  by brackets, has been  {E89 omitted}  and  {E90 filed}  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  {E91 amended}  . as applicable, sufficient to  {E92 grant}  the applicable license or sublicense under this Agreement, without  {E93 violating}  the terms of an agreement with a Third Party in existence as of the time such Party or its Affiliates would first be  {E94 required}  hereunder to  {E95 grant}  the other Party such (sub)license, right to  {E96 use}  or access. 1.12 "Controlled Affiliates" means, with respect to a Party, any Affiliate that is controlled (as defined in Section 1.1) by such Party. 1.13 "Data" means, subject to Section 1.51 (Ono Know-How) and Section 4.4(c)(ii), any and all research data, pharmacology data, preclinical data, clinical data and/or all Regulatory Filings and/or other regulatory documentation, information and {E198 submissions} pertaining to, or made in association with an IND, Marketing Approval {E202 Application}, Marketing {E201 Approval} or Pricing and Reimbursement {E222 Approvals}, or any Post-Approval Marketing Clinical {E171 Study} for each Product, in each case to the extent Controlled by a Party or its Affiliates as of the Effective  Date  or during the  term  of this Agreement. 1.14  "{E130 Development}" or " {E130 Develop}  " means non-clinical and clinical research and drug development {E130 activities}, including {E205 toxicology}, {E206 pharmacology}, statistical {E207 analysis}, Clinical {E218 Studies} (including pre- and post-approval {E209 studies}, Post-Approval Marketing Clinical {E171 Studies} and Investigator Sponsored Clinical {E211 Studies}), stability {E212 testing}, {E213 formulation}, process {E214 development}, quality assurance/control {E215 development}, regulatory {E216 affairs}, and regulatory {E217 activities} pertaining to designing and carrying out Clinical {E218 Studies} and obtaining and maintaining Marketing {E219 Approvals} (including pre-marketing {E220 activities} but excluding regulatory {E221 activities} directed to obtaining Pricing and Reimbursement {E222 Approvals}). 1.15 "Diligent {E231 Efforts}" means, with respect to the {E224 efforts} to be expended by a Party, with respect to any objective, reasonable, good faith {E225 efforts} to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances for such Party's benefit. Without  {E98 limiting}  the foregoing, with respect to {E226 efforts}  {E99 relating}  to the {E130 Development} of,  {E100 obtaining}  Marketing {E201 Approval} or Pricing and Reimbursement {E229 Approval} for, or {E134 Commercialization} of the Product, generally or with respect to any particular country, "Diligent {E231 Efforts}" means a sustained, continued and active {E231 commitment} of {E232 efforts} and resources by a Party consistent with those normally applied in the pharmaceutical industry with respect to compounds or products with similar market at a similar stage in the product life cycle that such Party is actively developing or commercializing (as applicable), taking into account the stage and risk of {E130 development} or {E134 commercialization} of the Product, issues of safety or efficacy, the cost effectiveness of {E236 efforts} or resources while optimizing profitability, the competitiveness of alternative Third Party compounds, products or generics that are or are expected to be in the marketplace, the scope and duration of Patents or other intellectual property rights related to the compound or product (including any Regulatory Exclusivity), the profitability of the Product (including pricing and reimbursement status achieved or likely to be achieved) or other relevant commercial factors,

5

[ * ] = Certain confidential information  {E101 contained}  in this document,  {E102 marked}  by brackets, has been  {E103 omitted}  and  {E104 filed}  separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of  1934 , as  {E105 amended}  . but not  {E106 taking}  into account (a) any other pharmaceutical product such Party is then  {E107 researching}  ,  {E108 developing}  or commercializing, alone or with one or more collaborators, or (b) any {E237 payments}  {E109 required}  to be  {E110 made}  to the other Party hereunder. 1.16 "EMA" means the European Medicines Agency, or any successor entity thereto performing similar functions. 1.17 "Encorafenib" means the compound known as LGX818, the chemical structure of which is depicted in Exhibit 1.22, as well as all salts, non-covalent complexes, hydrates, solvates, chelates, crystal polymorph, or radiolabeled equivalent thereof. 1.18  "FDA" means the U.S. Food and Drug Administration, or any successor entity thereto performing similar functions. 1.19 "{E241 Field}" means the {E238 diagnosis}, {E239 treatment} and/or prev{E240 e}ntion of diseases and conditions in humans.



#COLOR:E115=hsl(325, 100%, 80%)
#COLOR:E116=hsl(350, 100%, 80%)
#COLOR:E123=hsl(0, 100%, 80%)
#COLOR:E129=hsl(50, 100%, 80%)
#COLOR:E128=hsl(25, 100%, 80%)
#COLOR:E130=hsl(0, 100%, 70%)
#COLOR:E131=hsl(25, 100%, 70%)
#COLOR:E134=hsl(50, 100%, 70%)
#COLOR:E163=hsl(75, 100%, 80%)
#COLOR:E164=hsl(100, 100%, 80%)
#COLOR:E165=hsl(125, 100%, 80%)
#COLOR:E167=hsl(150, 100%, 80%)
#COLOR:E171=hsl(75, 100%, 70%)
#COLOR:E182=hsl(200, 100%, 80%)
#COLOR:E201=hsl(175, 100%, 80%)
#COLOR:E222=hsl(275, 100%, 80%)
#COLOR:E218=hsl(250, 100%, 80%)
#COLOR:E231=hsl(300, 100%, 80%)

#TOKENIZATION-TYPE:1

